Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 15, 2021 (6 years ago)

Restora Omega-3 enhanced Lactobacillus Casei KE-99 30 Capsules 1…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Restora Omega-3 enhanced Lactobacillus Casei KE-99 30 Capsules 1 A Day Nutritional Supplement NDC 52747-200-30 Marketed by US Pharmaceutical Corporation, P.O. Box 360465, Decatur, GA 30036

Affected NDC 52747-0200-30

Compare with the code on your package — it is the most precise check available.

Drug: Lactobacillus

Recalling firm
Cardinal Health Inc.
NDC code
52747-200-30
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0587-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lactobacillus recalls

See all
Class II · Moderate risk

Lactobacillus Acidophilus

Labeling: Label Mixup: LACTOBACILLUS ACIDOPHILUS, Tablet, 35 MILLION may have potentially been mislabeled as the following drug: REPAGLINIDE, Tablet, 1 mg, NDC 00169008281, Pedigree: W003924, EXP: 6/28/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-946-2014
Class II · Moderate risk

LACTOBACILLUS Tablet

Labeling: Label Mixup; LACTOBACILLUS Tablet may be potentially mislabeled as MULTIVITAMIN/MULTIMINERAL, Tablet, NDC 65162066850, Pedigree: AD62979_1, EXP: 5/23/2014; CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD62986_1, EXP: 5/23/2014; LITHIUM CARBONATE ER, Tablet, 225 mg (1/2 of 450 mg), NDC 00054002025, Pedigree: AD21790_25, EXP: 5/1/2014; OMEGA-3 FATTY ACID, Capsule, 100

Terminated Labeling / mix-up Aidapak Services, LLC D-700-2014
Class II · Moderate risk

LACTOBACILLUS ACIDOPHILUS Capsule

Labeling:Label Mixup; LACTOBACILLUS ACIDOPHILUS Capsule may be potentially mislabeled as CHOLECALCIFEROL, Tablet, 2000 units, NDC 00904615760, Pedigree: AD65311_1, EXP: 5/24/2014; PANCRELIPASE DR, Capsule, 24000 /76000 /120000 USP units, NDC 00032122401, Pedigree: AD65457_4, EXP: 5/24/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-618-2014
Class II · Moderate risk

LACTOBACILLUS GG Capsule

Labeling: Label Mixup; LACTOBACILLUS GG Capsule, 15 Billion Cells may be potentially mislabeled as ASPIRIN EC, Tablet, 325 mg, NDC 00904201360, Pedigree: W003356, EXP: 6/19/2014; ZONISAMIDE, Capsule, 100 mg, NDC 64679099001, Pedigree: W003786, EXP: 6/27/2014; VENLAFAXINE HCL, Tablet, 25 mg, NDC 00093019901, Pedigree: W003860, EXP: 6/27/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-581-2014
Class II · Moderate risk

LACTOBACILLUS GG Capsule

Labeling: Label Mixup; LACTOBACILLUS GG Capsule, 10 Billion Cells may be potentially mislabeled as guaiFENesin ER, Tablet, 600 mg, NDC 63824000815, Pedigree: AD21965_22, EXP: 5/1/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-580-2014

Other recalls by Cardinal Health Inc.

All 2021 recalls
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025